OncoMatch/Clinical Trials/NCT05657639
CAV Regimen for R/R AML
Is NCT05657639 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including CAV Regimen and MEC Regimen for acute myeloid leukemia.
Treatment: CAV Regimen · MEC Regimen — This study aims to investigate the efficacy and safety of cladribine, combined with low-dose cytarabine and venetoclax (CAV regimen) for relapsed/refractory acute myeloid leukemia (R/R AML).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard or intensive induction therapy
failure to attain CR following exposure to at least 2 courses of standard or intensive induction therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: patients who relapsed after allogeneic hematopoietic stem cell transplantation
Patients who relapsed after allogeneic hematopoietic stem cell transplantation
Cannot have received: organ transplant
Patients who have received organ transplants
Lab requirements
Kidney function
Ccr ≥ 50 ml/h
Liver function
total bilirubin ≤ 1.5x ULN, ALT/AST ≤ 2.5x ULN (or ≤ 1.5x ULN with liver involvement)
Cardiac function
No history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia, atrial fibrillation, II-degree heart block, myocardial infarction within one year, congestive heart failure, or symptomatic coronary heart disease requiring drug treatment
Liver function abnormalities (total bilirubin > 1.5 times of the upper limit of the normal range, ALT/AST > 2.5 times of the upper limit of the normal range or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of the normal range), or renal dysfunction (Ccr<50ml/h). Patients with a history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify